Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.
Advertisement

Related Content

Financings Of The Fortnight Ponders A Post-Euro Financing Environment
Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line
Disappointing Provenge Sales Stir Doubts About Demand
Disappointing Provenge Sales Stir Doubts About Demand
Dendreon Defends Provenge’s Stake Against Arrival Of Abiraterone

Topics

Advertisement
UsernamePublicRestriction

Register

PS073005

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel